Antibiotic-associated diarrhea

New England Journal of Medicine

Volumn 346, Issue 5, 2002, Pages 334-339

  Bartlett, John G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFIXIME; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BRONCHITIS; CASE REPORT; CLOSTRIDIUM DIFFICILE; DIARRHEA; DRUG INDUCED DISEASE; FEMALE; HUMAN; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; STAPHYLOCOCCUS AUREUS; COLON; DIFFERENTIAL DIAGNOSIS; ISOLATION AND PURIFICATION; MIDDLE AGED; PATHOLOGY; PRACTICE GUIDELINE; REVIEW; RISK FACTOR;

ANTI-BACTERIAL AGENTS; CEFIXIME; CLOSTRIDIUM DIFFICILE; COLON; DIAGNOSIS, DIFFERENTIAL; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HUMANS; MIDDLE AGED; PRACTICE GUIDELINES; RISK FACTORS;

EID: 0037204196     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMcp011603     Document Type: Article

References (45)

1. Antibiotic-associated diarrhea
2. Aspects of the safety profile of oral antimicrobial agents
3. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: A prospective study
4. Clostridium difficile colitis
5. Disease associated with Clostridium difficile infection
6. Diagnosis and treatment of Clostridium difficile colitis
7. Genotyping of enterotoxigenic Clostridium perfringens fecal isolates associated with antibiotic-associated diarrhea and food poisoning in North America
8. Staphylococcal enterocolitis following antibiotic therapy
9. Faecal candida and diarrhoea
10. In search of Salmonella's smoking gun
11. A nosocomial outbreak of fluoroquinolone-resistant salmonella infection
12. Salmonella colitis clinically presenting as a pseudomembranous colitis
13. Drug-induced diarrhoea
14. Mechanisms and management of antibiotic-associated diarrhea
15. The effect of faecal enema on five microflora-associated characteristics in patients with antibiotic-associated diarrhoea
16. Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations
17. Nosocomial acquisition of Clostridium difficile infection
18. A prospective nationwide study of Clostridium difficile-associated diarrhea in Sweden
19. Antimicrobial agents implicated in Clostridium difficile toxin-associated diarrhea or colitis
20. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A
21. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea
22. Leukocytosis as a harbinger and surrogate marker of Clostridium difficile infection in hospitalized patients with diarrhea
23. Clostridium difficile colitis: An efficient clinical approach to diagnosis
24. Practice guidelines for the management of infectious diarrhea
25. Clostridium difficile-associated diarrhea: A review
26. Enzyme immunoassays for detection of Clostridium difficile toxins A and B in fecal specimens
27. Comparison of three enzyme immunoassays, a cytotoxicity assay, and toxigenic culture for diagnosis of Clostridium difficile-associated diarrhea
28. Comparison of four commercially available rapid enzyme immunoassays with cytotoxin assay for detection of Clostridium difficile toxin(s) from stool specimens
29. Mory E Laboratory diagnosis of Clostridium difficile-associated diarrhea and colitis: Usefulness of premier cytoclone A+B enzyme immunoassay for combined detection of stool toxins and toxigenic C. difficile strains
30. Role of culture and toxin detection in laboratory testing for diagnosis of Clostridium difficile-associated diarrhea
31. Fatal pseudomembranous colitis associated with a variant Clostridium difficile strain not detected by toxin A immunoassay
32. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis
33. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea
34. Treatment of Clostridium difficile colitis
35. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease
36. Recurrent Clostridium difficile disease: Epidemiology and clinical characteristics
37. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG
38. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis
39. Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces
40. Clostridium difficile-associated diarrhea and colitis
41. Epidemiology of antibiotic-associated colitis: Isolation of Clostridium difficile from the hospital environment
42. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals
43. Hospital-wide restriction of clindamycin: Effect on the incidence of Clostridium difficile-associated diarrhea and cost
44. Derivation and validation of guidelines for stool cultures for enteropathogenic bacteria other than Clostridium difficile in hospitalized adults
45. Recommendations for preventing the spread of vancomycin resistance: Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC)